Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease

Ann Intern Med. 2019 Aug 20;171(4):JC15. doi: 10.7326/ACPJ201908200-015.
No abstract available

Publication types

  • Comment

MeSH terms

  • Canagliflozin
  • Diabetes Mellitus, Type 2*
  • Humans
  • Kidney
  • Renal Insufficiency, Chronic*
  • Sodium-Glucose Transporter 2 Inhibitors*

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin